ZBH Stock Recent News

Zimmer Biomet is suffering due to macroeconomic uncertainties, pricing pressure and unfavorable currency fluctuations.

Zimmer Biomet shares at $105 reveal value at 13 times adjusted earnings, as the company continues to grow despite a GLP-1 drug overhang. The 2015 Zimmer Biomet merger hasn't been fully delivered, but recent organic growth and M&A actions are promising, with mid-single digit sales growth projected. The $1.2 billion Paragon 28 acquisition enhances foot and ankle orthopedics, despite short-term EPS dilution, and boosts Zimmer Biomet's growth profile.

Zimmer Biomet benefits from its diversified portfolio outside of core orthopedics and the company's strategic investments in attractive, higher-growth segments.

On Thursday, Zimmer Biomet Holdings, Inc ZBH reported fourth-quarter adjusted EPS of $2.31, up from $2.20 a year ago, beating the Street estimates of $2.30.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH ) Q4 2024 Earnings Conference Call February 6, 2025 8:30 AM ET Company Participants David DeMartino - Senior Vice President-Investor Relations Ivan Tornos - President and Chief Executive Officer Suketu Upadhyay - CFO and EVP, Finance, Operations and Supply Chain Conference Call Participants Robbie Marcus - JPMorgan Patrick Wood - Morgan Stanley Steven Lichtman - Oppenheimer and Company Matt Taylor - Jefferies David Roman - Goldman Sachs Vik Chopra - Wells Fargo Ryan Zimmerman - BTIG Danielle Antalffy - UBS Travis Steed - Bank of America Rick Wise - Stifel Matt Miksic - Barclays Jayson Bedford - Raymond James Operator Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet Fourth Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded today, February 06, 2025.

Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Medical device maker Zimmer Biomet Holdings forecast full-year adjusted profit below Wall Street estimates on Thursday, as it anticipates a hit from a strong dollar.

Zimmer Biomet (ZBH) came out with quarterly earnings of $2.31 per share, beating the Zacks Consensus Estimate of $2.30 per share. This compares to earnings of $2.20 per share a year ago.

Fourth quarter net sales of $2.023 billion increased 4.3% and 4.9% on a constant currency1 basis Fourth quarter diluted earnings per share were $1.20; adjusted1 diluted earnings per share were $2.31 Full-year net sales of $7.679 billion increased 3.8% and 4.8% on a constant currency1 basis Full-year diluted earnings per share were $4.43; adjusted1 diluted earnings per share were $8.00 Company provides full-year 2025 financial guidance WARSAW, Ind. , Feb. 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter and year ended December 31, 2024.

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Zimmer (ZBH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.